The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.
The partners will identify patients with gastrointestinal or endometrial cancers who may benefit from immune checkpoint inhibitor therapy using Biotype's technology.
